Stock Analysis
- Australia
- /
- Personal Products
- /
- ASX:HPC
Hydration Pharmaceuticals Full Year 2023 Earnings: US$0.04 loss per share (vs US$0.065 loss in FY 2022)
Hydration Pharmaceuticals (ASX:HPC) Full Year 2023 Results
Key Financial Results
- Revenue: US$10.0m (up 10% from FY 2022).
- Net loss: US$8.10m (loss narrowed by 24% from FY 2022).
- US$0.04 loss per share (improved from US$0.065 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hydration Pharmaceuticals shares are up 6.7% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Hydration Pharmaceuticals has 6 warning signs we think you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Hydration Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:HPC
Hydration Pharmaceuticals
The Hydration Pharmaceuticals Company Limited markets and sells a range of liquid, tablet, and powder healthy hydration products in Australia, the Unites States, and Canada.